Research progress on treatment of Parkinson disease-related pain with traditional Chinese and Western medicine

doi:10.16138/j.1673-6087.2025.01.10

Abstract

Abstract:

Pain is one of the most common non-motor symptoms of Parkinson disease, with complex pathogenesis and clinical classification. The current treatment in Western medicine for pain in Parkinson disease mainly focuses on dopamine replacement therapy, which can only solve a portion of the pain issues. However, long-term use of Western medications inevitably leads to motor complications and drug side effects, making the effect of treatment often insufficient. Traditional Chinese medicine has unique advantages in pain management. Therefore, this article summarizes recent literature on the treatment of Parkinson disease pain with Western and traditional Chinese medicine, aiming to provide scientific references and therapeutic strategies for the integrated treatment of the disease with traditional Chinese and Western medicine.

Key words: Parkinson disease, Pain, Integrated traditional Chinese and Western medicine, Research progress

CLC Number:

R742

SUN Qian, LIN Shiyu, XIA Mengjie, ZHOU Haiyan, WANG Xiuwei. Research progress on treatment of Parkinson disease-related pain with traditional Chinese and Western medicine[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(01): 50-53.

References 44

[1]	Silverdale MA, Kobylecki C, Kass-lliyya L, et al. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson’s disease[J]. Parkinsonism Relat Disord, 2018,56:27-32.
[2]	Mylius V, Perez Lloret S, Cury RG, et al. The Parkinson disease pain classification system: results from an international mechanism-based classification approach[J]. Pain, 2021, 162(4):1201-1210.
[3]	Raja SN, Carr DB, Cohen M, et al. The revised international association for the study of pain definition of pain: concepts, challenges, and compromises[J]. Pain, 2020, 161(9):1976-1982.
[4]	Allen NE, Romaliiska O, Naisby J. Pain and the non-pharmacological management of pain in people with Parkinson’s disease[J]. J Parkinsons Dis, 2024, 14(s1):S65-S80.
[5]	Broetz D, Eichner M, Gasser T, et al. Radicular and nonradicular back pain in Parkinson’s disease: a controlled study[J]. Mov Disord, 2007, 22(6):853-856.
[6]	Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states?[J] Pain, 2016, 157(7):1382-1386. doi: 10.1097/j.pain.0000000000000507 pmid: 26835783
[7]	Fitzcharles MA, Cohen SP, Clauw DJ, et al. Nociplastic pain: towards an understanding of prevalent pain conditions[J]. Lancet, 2021, 397(10289):2098-2110. doi: 10.1016/S0140-6736(21)00392-5 pmid: 34062144
[8]	Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances[J]. Lancet, 2021, 397(10289):2082-2097. doi: 10.1016/S0140-6736(21)00393-7 pmid: 34062143
[9]	Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson’s disease: clinical and pharmacological features[J]. Ann Neurol, 1988, 23(1):73-78. doi: 10.1002/ana.410230112 pmid: 3345068
[10]	Battista AF, Wolff BB. Levodopa and induced-pain response[J]. Arch Intern Med, 1973, 132(1):70-74. pmid: 4716428
[11]	Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study[J]. Mov Disord, 2005, 20(12):1557-1563.
[12]	Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RⅢreflex study[J]. J Neurol Neurosurg Psychiatry, 2007, 78(10):1140-1142. doi: 10.1136/jnnp.2007.120212 pmid: 17504881
[13]	Rascol O, Zesiewicz T, Chaudhuri KR, et al. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson’s disease-associated chronic pain[J]. J Clin Pharmacol, 2016, 56(7):852-861.
[14]	Raeder V, Boura I, Leta V, et al. Rotigotine transdermal patch for motor and non-motor Parkinson’s disease: a review of 12 years’ clinical experience[J]. CNS Drugs, 2021, 35(2):215-231.
[15]	Hattori N, Tsuboi Y, Yamamoto A, et al. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled, phaseⅡ /Ⅲ study[J]. Parkinsonism Relat Disord, 2020,75:17-23.
[16]	Kurihara K, Mishima T, Fujioka S, Tsuboi Y. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson’s disease[J]. Expert Opin Drug Saf, 2022, 21(2):137-147.
[17]	Chaudhuri KR, Odin P, Ferreira JJ, et al. Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (opicapone effect on motor fluctuations and pain) trial[J]. BMC Neurol, 2022, 22(1):88.
[18]	Qureshi AR, Rana AQ, Malik SH, et al. Comprehensive examination of therapies for pain in Parkinson’s disease: a systematic review and meta-analysis[J]. Neuroepidemiology, 2018, 51(3-4):190-206. doi: 10.1159/000492221 pmid: 30153669
[19]	Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease[J]. Clin Neuropharmacol, 2007, 30(4):201-205. doi: 10.1097/wnf.0b013e3180340319 pmid: 17762316
[20]	Sidhu HS, Sadhotra A. Current status of the new antiepileptic drugs in chronic pain[J]. Front Pharmacol, 2016,7:276.
[21]	Ford B. Pain in Parkinson’s disease[J]. Mov Disord, 2010,25 Suppl 1:S98-S103.
[22]	Argoff CE. New analgesics for neuropathic pain: the lidocaine patch[J]. Clin J Pain, 2000, 16(2 Suppl):S62-S66.
[23]	Viseux FJF, Delval A, Simoneau M, Defebvre L. Pain and Parkinson’s disease: current mechanism and management updates[J]. Eur J Pain, 2023, 27(5):553-567.
[24]	上海中西医结合学会慢性神经系统疾病专业委员会. 帕金森病运动处方专家共识[J]. 同济大学学报(医学版), 2021, 42(6):729-735.
[25]	武琪, 刘志坚, 程玲, 等. 水疗法对轻中度帕金森患者作用效果的荟萃分析[J]. 临床与病理杂志, 2021, 41(2):374-382.
[26]	Yang QH, Zhang YH, Du SH, et al. Non-invasive brain stimulation for central neuropathic pain[J]. Front Mol Neurosci, 2022,15:879909.
[27]	Flouty O, Yamamoto K, Germann J, et al. Idiopathic Parkinson’s disease and chronic pain in the era of deep brain stimulation: a systematic review and meta-analysis[J]. J Neurosurg, 2022, 137(6):1821-1830.
[28]	Zimmers S, Robieux L, Bungener C. Towards a better comprehension and management of pain and psychological distress in Parkinson’s: the role of catastrophizing[J]. J Geriatr Psychiatry Neurol, 2023, 36(5):351-365.
[29]	Pickut B, Vanneste S, Hirsch MA, et al. Mindfulness training among individuals with Parkinson’s disease: Neurobehavioral Effects[J]. Parkinsons Dis, 2015,2015:816404.
[30]	汪海芹, 蔡忠明. 大定风珠治疗帕金森病40例临床观察[J]. 世界最新医学信息文摘(连续型电子期刊), 2019, 19(26):155.
[31]	侯宇, 马效麟, 张婷, 等. 补肾养肝息风汤对肝肾阴虚型帕金森病患者综合功能的影响[J]. 湖北中医药大学学报, 2021, 23(3):66-68.
[32]	戈盾. 止颤汤合芍药甘草汤治疗帕金森病疼痛的临床疗效观察[J]. 内蒙古中医药, 2017, 36(14):44-45.
[33]	郑春叶, 吕少华, 黄强, 等. 加味桂枝加葛根汤治疗帕金森病疼痛40例临床观察[J]. 中国民间疗法, 2018, 26(11):37-38.
[34]	张秀琳, 惠振, 王苏雷, 等. 加减地黄饮子治疗帕金森病疼痛临床研究[J]. 陕西中医, 2021, 42(5):620-624.
[35]	王秀薇. 胡建华平肝熄风通络法治疗神经系统疾病[J]. 上海中医药杂志, 2006(12):9-10.
[36]	Feng Z, Cui S, Yang H, et al. Acupuncture for neuropathic pain: A meta-analysis of randomized control trials[J]. Front Neurol, 2023,13:1076993.
[37]	Lee SH, Lim S. Clinical effectiveness of acupuncture on Parkinson disease: a PRISMA-compliant systematic review and meta-analysis[J]. Medicine (Baltimore), 2017, 96(3):e5836.
[38]	Yu SW, Lin SH, Tsai CC, et al. Acupuncture effect and mechanism for treating pain in patients with Parkinson’s disease[J]. Front Neurol, 2019,10:1114.
[39]	Shaosong W, Jingqing S, Qingyin F, et al. Effectivenss of electroacupuncture for skeletal muscle pain in Parkinson’s disease: a clinical randomized controlled trial[J]. J Tradit Chin Med, 2024, 44(2):388-395. doi: 10.19852/j.cnki.jtcm.20240203.004
[40]	于楠楠, 马琳, 毕海洋, 等. 浮针治疗帕金森病伴发四肢疼痛临床研究[J]. 针灸临床杂志, 2020, 36(1):37-40.
[41]	Fusaro M, Bufacchi RJ, Nicolardi V, et al. The analgesic power of pleasant touch in individuals with chronic pain: recent findings and new insights[J]. Front Integr Neurosci, 2022,16:956510.
[42]	Buhmann C, Wrobel N, Grashorn W, et al. Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy[J]. J Neurol, 2017, 264(4):758-769. doi: 10.1007/s00415-017-8426-y pmid: 28243753
[43]	Deuel LM, Seeberger LC. Complementary therapies in parkinson disease: a review of acupuncture, tai chi, qi gong, yoga, and cannabis[J]. Neurotherapeutics, 2020, 17(4):1434-1455.
[44]	蔡鸣春, 顾炜萍, 王厹东, 等. 中药热熨护理对帕金森病伴发肌肉骨骼性疼痛的影响研究[J]. 现代中西医结合杂志, 2022, 31(14):2009-2011.